DOI QR코드

DOI QR Code

Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas

  • Liu, Chun-Xia (Department of Pathology, Shihezi University School of Medicine) ;
  • Li, Xiao-Ying (Department of Pathology, Shihezi University School of Medicine) ;
  • Li, Cheng-Fang (Department of Pathology, Shihezi University School of Medicine) ;
  • Chen, Yun-Zhao (Department of Pathology, Shihezi University School of Medicine) ;
  • Cui, Xiao-Bin (Department of Pathology, Shihezi University School of Medicine) ;
  • Hu, Jian-Ming (Department of Pathology, Shihezi University School of Medicine) ;
  • Li, Feng (Department of Pathology, Shihezi University School of Medicine)
  • Published : 2014.02.28

Abstract

The rhabdomyosarcoma (RMS) is the most common type of soft tissue tumor in children and adolescents; yet only a few screens for oncogenic mutations have been conducted for RMS. To identify novel mutations and potential therapeutic targets, we conducted a high-throughput Sequenom mass spectrometry-based analysis of 238 known mutations in 19 oncogenes in 17 primary formalin-fixed paraffin-embedded RMS tissue samples and two RMS cell lines. Mutations were detected in 31.6% (6 of 19) of the RMS specimens. Specifically, mutations in the NRAS gene were found in 27.3% (3 of 11) of embryonal RMS cases, while mutations in NRAS, HRAS, and PIK3CA genes were identified in 37.5% (3 of 8) of alveolar RMS (ARMS) cases; moreover, PIK3CA mutations were found in 25% (2 of 8) of ARMS specimens. The results demonstrate that tumor profiling in archival tissue samples is a useful tool for identifying diagnostic markers and potential therapeutic targets and suggests that these HRAS/ PIK3CA mutations play a critical role in the genesis of RMS.

Keywords

Rhabdomyosarcoma;massARRAY system;mutation;oncogene;HRAS/PIK3CA

References

  1. Kratz CP, Steinemann D, Niemeyer CM, et al (2007). Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome, Hum Mol Genet, 16, 374-9. https://doi.org/10.1093/hmg/ddl458
  2. Anderson J, Gordon A, Pritchard-Jones K, et al (1999). Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer, 26, 275-85. https://doi.org/10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3
  3. Chen Y, Takita J, Hiwatari M, et al (2006). Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer, 45, 583-91. https://doi.org/10.1002/gcc.20322
  4. De Giovanni C, Landuzzi L, Nicoletti G, et al (2009). Molecular and cellular biology of rhabdomyosarcoma. Future Oncol, 5, 1449-75. https://doi.org/10.2217/fon.09.97
  5. Langenau DM, Keefe MD, Storer NY, et al (2007). Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev, 21, 1382-95. https://doi.org/10.1101/gad.1545007
  6. Martinelli S, McDowell HP, Vigne SD, et al (2009). RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer, 48, 975-82. https://doi.org/10.1002/gcc.20702
  7. Paulson V, Chandler G, Rakheja D, et al (2011). Highresolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer, 50, 397-408. https://doi.org/10.1002/gcc.20864
  8. Shukla N, Ameur N, Yilmaz I, et al (2012). Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res, 18, 748-57. https://doi.org/10.1158/1078-0432.CCR-11-2056
  9. Sorensen PH, Lynch JC, Qualman SJ, et al (2002). PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol, 20, 2672-9. https://doi.org/10.1200/JCO.2002.03.137
  10. Xin G, Dong-Sheng H, Ji-Tong Sh, et al (2013). Multidisciplinary collaborative therapy for 30 children with orbital rhabdomyosarcoma. Asian Pac J Cancer Prev, 14, 4641-6. https://doi.org/10.7314/APJCP.2013.14.8.4641
  11. Stratton MR, Fisher C, Gusterson BA, et al (1989). Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res, 49, 6324-7.
  12. Taylor JG, Cheuk AT, Tsang PS, et al (2009). Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest, 119, 3395-407.
  13. Thomas RK, Baker AC, Debiasi RM, et al (2007). Highthroughput oncogene mutation profiling in human cancer. Nat Genet, 39, 347-51. https://doi.org/10.1038/ng1975

Cited by

  1. Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9327
  2. Rhabdomyosarcoma - an Epidemiological and Histopathologic Study of 277 Cases from a Major Tertiary Care Center in Karachi, Pakistan vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.757
  3. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-016-4924-2